Coherus Oncology (NASDAQ:CHRS) outlined progress on its transition to an “innovative oncology” company during its ...
Recently published Neuroendocrine Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, neuroendocrine carcinoma emerging drugs, market share of ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果